Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04518306 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
A Phase 3 study, sponsored by George Medicines PTY Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 755
- Enrollment target
NCT04518306: Completed Phase 3 study, sponsored by George Medicines PTY Limited.
NCT04518306 is a Phase 3 study that has completed, run by George Medicines PTY Limited. The registered enrollment target is 755 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04518306, a Phase 3 study, has completed, sponsored by George Medicines PTY Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 755 participants
- Enrollment target
Study Summary
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.
Interventions
- DRUG Placebo
- DRUG Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- DRUG Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04518306
The ClinicalTrials.gov registry entry for NCT04518306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Medicines PTY Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04518306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04518306 about?
NCT04518306 is a clinical study titled "Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension". Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to i...
What is the current status of trial NCT04518306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 755 participants. The study started on 2021-06-14. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT04518306?
The interventions under investigation include: Placebo (DRUG), Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (DRUG), Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg (DRUG).
Who is sponsoring clinical trial NCT04518306?
This trial is sponsored by George Medicines PTY Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.